1. At a Glance
Mangalam Drugs was born in 1977, makes anti-malarial and anti-viral APIs, but currently needs an anti-loss vaccine. Despite sales of nearly ₹300 Cr, the company posted a loss of ₹9.5 Cr in FY25. Stock is at ₹80, market cap just ₹126 Cr — basically, one Titan showroom employee bonus pool. Investors are stuck like patients on expired chloroquine tablets.
2. Introduction
Picture this: a company once so pious it worked with the Clinton Foundation to supply life-saving anti-malarials. Fast-forward to now, and the company is manufacturing losses instead of drugs.
Mangalam Drugs is in the API and intermediates business: artemisinin for malaria, acyclovir for herpes, bisoprolol for BP, efavirenz for HIV — basically, if your doctor has written it, Mangalam has probably tried (and failed) to profit from it.
But the glamour ends when you look at returns: stock down -35% in one year, -9% CAGR over 5 years. ROE is crawling at 4.7%, while debt has climbed to ₹89 Cr. Promoters hold ~50%, but 13% is pledged — because clearly even they needed a loan against their shares to survive.
So, is Mangalam a turnaround story waiting for a vaccine, or a pharma zombie still alive only because investors forgot to delist it? Let’s autopsy.
3. Business Model (WTF Do They Even Do?)
Mangalam makes:
- APIs like Acyclovir, Amodiaquine, Chloroquine, Efavirenz, Tenofovir.
- Intermediates like Dichloroquinoline and Disoproxil.
- Specialty chemicals like menthol (yes, your toothpaste cooling agent).
Product categories: Anti-malarial, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-bacterial. Basically, everything “anti-” except anti-loss.
Revenue breakup FY23:
- 89% from product sales,
- 5% trading,
- 4% engineering services,
- 2% forex gains.
Future plans? Tie-up in Africa for anti-malarial plant + new APIs for inflammation and osteoporosis. Nice buzzwords, but given their track record, investors may need anti-depressants before results
